Functional validation via in vitro chemotaxis assays and in vivo xenograft models demonstrates that CXCL10 overexpression suppresses tumor growth by enhancing effector immune cell infiltration, while CCL20 promotes Treg accumulation without impeding tumor progression. The gene discussed is CXCL10; the disease is neoplasm.